Prognostic is very modest with an overall 5 years survival rate at less than 4%, the lowest of all solid tumours. Medical or surgical palliative treatment can significantly increase the comfort of life, but only modestly increases survival. Only in a subset of patients, with T1 tumour (TNM classification), resectional surgery can be curative, with a 5 year survival rate reported was 20% (3). Adiponectin is an adipokin product of mature adipocyte, reduced in the case of insulin resistance and positively correlated with insulin sensitivity. Adiponectin regulates intracellular pathways of protein Inhibitors,research,lifescience,medical kinase activated by AMP (AMP-kinase), of c-JUN and c-JUN N-terminal kinase (JNK) and of the signal that transcribes

and activates transcription 3 (STAT3). Therefore, adiponectin is an anti-inflammatory, anti-angiogenic and Inhibitors,research,lifescience,medical a block for cell growth. Circulating concentrations of adiponectin are inversely correlated to the risk of several cancers: breast cancer (4), endometrium (5), prostate (6), clear cell cancer kidney (7), stomach cancer (8) and leukemia (9). Prospective studies have shown that there is, at distance, a major risk of breast cancer (10), endometrial (11) and colo-rectal cancer

(12) in postmenopausal women if adiponectin serum level is low. Adiponectin present a direct antitumor (13) and proapoptotic effect. Conversely, in pancreatic cancer, results about Inhibitors,research,lifescience,medical ADP are conflicted (14),(15). The principal aim of our study was to compare Inhibitors,research,lifescience,medical ADP concentrations in two groups of cancer (GSK1210151A colorectal cancer and pancreas cancer) matched on age, sex and tumour staging (metastatic

or non metastatic). Patients and methods This prospective study included all consecutive patients with a new diagnosis of pancreatic adenocarcinoma followed in a referent university hospital between January 2006 and September 2007. The control group included patients with new diagnosis of colorectal carcinoma diagnosed in the same period and matched for sex, age and tumour staging (metastatic or non metastatic tumour), according to the sixth edition of American Joint Committee on Cancer: tumour, node, metastasis (TNM) classification Inhibitors,research,lifescience,medical system. In all cases diagnosis was histological or cytological. All patients were informed and signed a consent paper. Patients on chemotherapy or on antidiabetic treatment were excluded from the study. All patients were characterized by age, sex, body mass index (BMI) before and at the moment of diagnosis, the Suplatast tosilate presence of diabetes according to the criteria of the American Diabetes Association. When diabetes was pre-existing, we evaluated the interval between diagnosis of diabetes and diagnosis of pancreatic cancer. We noted a family history of diabetes, and the presence or absence of an associated dysmetabolic syndrome: hypertension, dyslipidemia, obesity. Tumour data were: stage, size and tumour markers (CEA and CA 19-9); patients were divided into two groups: resectable cancer or locally advanced/metastatic.